Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection-Reference-Cited by-同舟云学术

Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection

Published:2023-05-23 Issue:9 Volume:42 Page:2369-2376
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Liu Suling^ORCID,He Ziye,Wu Wenjing,Jin Hua,Cui Yang^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s10067-023-06630-8.pdf

Reference29 articles.

1. Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390:73–84. https://doi.org/10.1016/s0140-6736(16)31591-4

2. Robinson PC, van der Linden S, Khan MA, Taylor WJ (2021) Axial spondyloarthritis: concept, construct, classification and implications for therapy. Nat Rev Rheumatol 17:109–118. https://doi.org/10.1038/s41584-020-00552-4

3. Ward MM, Deodhar A et al (2019) 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 71:1599–1613. https://doi.org/10.1002/art.41042

4. Baeten D, Sieper J et al (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373:2534–2548. https://doi.org/10.1056/NEJMoa1505066

5. van der Heijde D, Ramiro S et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76:978–991. https://doi.org/10.1136/annrheumdis-2016-210770

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus;Journal of the European Academy of Dermatology and Venereology;2024-08-16

2. Reactivation Risk of Latent Tuberculosis or Inactive Hepatitis B Virus Infection and Effectiveness of Ustekinumab in Chinese Plaque Psoriasis Patients: A 28-Week Retrospective, Observational Study;Clinical, Cosmetic and Investigational Dermatology;2024-06

3. The use of secukinumab in patients with chronic infections;JEADV Clinical Practice;2024-01-20